Northwest Bio ($NWBO) Files Application for Commercial Cellular Therapy Manufacturing скачать в хорошем качестве

Northwest Bio ($NWBO) Files Application for Commercial Cellular Therapy Manufacturing

Northwest Biotherapeutics (OTCMKTS: $NWBO), a biotech company developing DCVax® personalized immune therapies for solid tumor cancers, has submitted an application for approval of a commercial cellular therapy manufacturing license at its production facility in the United Kingdom. The most recent application submission builds on three licenses received for the facility in 2021. Northwest Bio has targeted year end for receipt of the commercial manufacturing license. In preparation of obtaining the license, Northwest Bio has created additional standard operating procedures, worked to validate transport logistics, and qualified several new pieces of equipment. Additionally, the company has completed delivery and installation of an automated system for a fill and finish of the DCVax-L product. Northwest Bio is developing a broad platform technology for DCVax® dendritic cell-based vaccines. The Company's lead program is a 331-patient Phase III trial of DCVax®-L for newly diagnosed Glioblastoma multiforme, the most aggressive and lethal form of brain cancer. A Phase III trial has been completed and top line data has been presented. The Company is also pursuing development of DCVax®-Direct for inoperable solid tumor cancers. Northwest Bio has completed a 40-patient Phase I trial and plans to prepare for Phase II trials. Shares of Northwest Biotherapeutics trade on the OTC under the ticker symbol NWBO. For more information visit www.greenstocksnews.com #cleantech #biotechnology #cancertreatment #biotech